Post by Annals of Research in Oncology

🔬 𝐋𝐈𝐪𝐮𝐢𝐝 𝐛𝐢𝐨𝐩𝐬𝐲 𝐚𝐧𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐨𝐟 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 (𝐋𝐈𝐃𝐈𝐀) 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐝𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐚𝐧𝐝 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐢𝐧 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫: 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 LIquid biopsy is used for both early screening of malignancy and diagnosing minimal residual disease. The analysis of morphostructural data obtained by imaging, correlated with the genetic/molecular results of liquid biopsy, could provide useful predictive factors for early diagnosis and predicting the response to anti-cancer drugs. The study aims to design and develop a report structured in CT with contrast media, which includes, in addition to the subjective evaluation of the radiologist, a quantitative/objective assessment of lung cancer (LC) with features that describe the texture and morphology of the lesion. The latest #report authored by Drs. Maria Paola Belfiore et al.* presents a workflow that extract and analyze contrast-enhanced CT images for accurate characterization of lung cancer lesions. These imaging findings are correlated with genetic mutations and epigenetic changes detected through liquid biopsy, aiming to reduce unnecessary biopsies and support personalized treatment for lung cancer patients. 📌 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: https://lnkd.in/ddq2bzNQ Editors in Chief, Professors Antonio Giordano, Sbarro Health Research Organization & 𝗖𝗮𝗿𝗺𝗶𝗻𝗲 𝗣𝗶𝗻𝘁𝗼, AUSL Reggio Emilia Executive Editor, Professor Francesca Pentimalli, Università LUM Edra S.p.A. #LiquidBiopsy #LungCancer #CancerScreening #CancerResearch #Oncology *Drs. Michele Caraglia, Carminia Maria Della Corte, Floriana Morgillo, Gaetano Di Guida, Giovanni Ciani, Carlotta Genco, Gianluca Russo, Mario Sansone, Umberto Malapelle, Carmela Nappi, Salvatore Cappabianca